The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare ...

Semaglutide, a GLP-1R agonist developed by Denmark’s Novo Nordisk as Ozempic, initially for type 2 diabetes, and marketed ...

Cipla is looking at the whole GLP-1 category and not just Semaglutide alone, says Cipla CEO Umang Vohra in a post-results ...

If all the Instagram posts and podcasts filling my feed are any indication, lots of 40- and 50-something women are spending ...

WOMEN and older adults who use increasingly popular weight-loss drug semaglutide could protect themselves from a common side ...

Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...

India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Indian drugmaker, Cipla Ltd, sees GLP-1 drugs, used to treat type-2 diabetes and obesity, as a significant new therapy opportunity in the Indian market.

More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...

New research reveals GLP-1 drugs like Ozempic may reduce stroke risk and improve recovery. At the 22nd Annual Meeting of the ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...